Tiffany Ni

Ms. Tiffany Ni

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MAM‐Ashraf Altesha
M‐Ashraf Altesha
TNTiffany Ni
Tiffany Ni
AKAfaan Khan
Afaan Khan
KLKexiang Liu
Kexiang Liu
XZXiufen Zheng
Xiufen Zheng

6 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
NVNicolas Voizard
Nicolas Voizard
TNTiffany Ni
Tiffany Ni
AKAlex Kiss
Alex Kiss
RPRobyn Pugash
Robyn Pugash
MRMichael J. Raphael
Michael J. Raphael
EDElizabeth David
Elizabeth David
The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes.

11 December 2023 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
Angela Kwan, MD, MScAngela Kwan, MD, MSc
Angela Kwan, MD, MSc
JPJacob S. Portnoff
Jacob S. Portnoff
Khaled Al-KassimiKhaled Al-Kassimi
Khaled Al-Kassimi
GSGurkaran Singh
Gurkaran Singh
MHMehrshad Hanafimosalman
Mehrshad Hanafimosalman
RMRoger McIntyre
Roger McIntyre

7 June 2023 in Plastic Surgery
Verified
Journal Article
Open access
TNTiffany Ni
Tiffany Ni
UCUrska Cebron
Urska Cebron
KZKevin J. Zuo
Kevin J. Zuo
SSStephanie Stefaniuk
Stephanie Stefaniuk
LSLaura Snell
Laura Snell
JDJana Dengler
Jana Dengler
Purpose: Professional achievement awards are an important factor in recruitment, promotion, and faculty review within academic institutions. Studies have shown that subconscious, gender-based assumptions of individuals and their work in traditionally male-dominated fields lead to more positive evaluations of men than women, a phenomenon present among scientific and medical award committees. This study examined gender representation among recipients of major North American plastic surgery society awards over the last 50 years. Methods: Recipient lists of major achievement awards bestowed by ten American and Canadian plastic surgery societies between 1970 and 2020 were accessed online or by direct contact with the society. Awardee gender, institution affiliation, graduation year, fellowship status, and additional major awards received were recorded. Comparisons were made between gender representation among society presidents, board membership, general society memberships, attending physicians, and plastic surgery residency enrolment. Results: Thirty-two major awards given by ten plastic surgery societies were included. Six hundred and twenty-five awards were conferred, of which 47 recipients were female (7.5%). Of the 121 individuals that received multiple major awards, 8 were female. Two-thirds of female awardees (72%) were clinical plastic surgeons and the remainder were scientists. Over the past 50 years, there has been a gradual increase in the proportion of female award winners. Conclusions: Despite a gradual increase in the proportion of female awardees in major plastic surgery societies, female plastic surgeons remain underrepresented among awardees, with less than 10% of major awards conferred to females.

24 November 2022 in Canadian Association of Radiologists Journal
Verified
Journal Article
Open access
TNTiffany Ni
Tiffany Ni
FAFahmeen J. Afgani
Fahmeen J. Afgani
CBConnor T.A. Brenna
Connor T.A. Brenna
NPNikita Patel
Nikita Patel
ENElsie Thao Nguyen
Elsie Thao Nguyen
Objective: While numerous recent guidelines support coronary computed tomography angiography (CTA) as a first-line test for stable chest pain, it remains underutilized by primary care physicians (PCPs). We aimed to evaluate cardiac investigation ordering practices following education sessions, as well as the total number of downstream tests and time to diagnosis for patients presenting with stable chest pain. Methods: A retrospective chart review was completed for eligible patients assessed at the Women's College Hospital Family Practice Health Centre between 2017 and 2019 following the education sessions. The outcome measures were first-choice cardiac investigation, additional downstream testing, time from presentation to first investigation, and time to final diagnosis. Results: 419 patients were included in the final analysis (74.70% female; mean age 61 ± 11 years). Coronary CTA requests by PCPs increased between 2017 and 2019 (18 vs 72 tests; P < .0001). When coronary CTA was the first-line test, patients were less likely to receive additional downstream testing when compared to those receiving other first-line investigations ( P < .0001). Coronary CTA was associated with longer time to diagnosis than stress echocardiography (47 ± 45 vs 27 ± 36 days; P = .0068) due to limited availability of coronary CTA appointment times. There was no significant difference in time to final diagnosis among the cardiac imaging modalities observed in the cohort ( P = .0623). Conclusion: Utilization of coronary CTA as the first-line test for stable chest pain increased following our education sessions targeting PCPs. Coronary CTA was associated with less downstream testing compared to other non-invasive cardiac investigations.

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SSSureka Selvakumaran
Sureka Selvakumaran
SHSarah Hayes
Sarah Hayes
QLQingfan Liu
Qingfan Liu
TNTiffany Ni
Tiffany Ni
PWPaul Walton
Paul Walton
BABrian Allman
Brian Allman
Hearing loss is a chronic health condition that affects millions of people worldwide. In addition to age‐related hearing loss, excessive exposure to loud noise or ototoxic chemotherapy drugs (e.g., cisplatin) can also lead to hearing impairment via oxidative stress in the sensory cells in the inner ear (cochlea). In such cases, the endogenous antioxidant enzymes (e.g., catalase) in the cochlea that normally mitigate the accumulation of reactive oxygen species become overwhelmed, resulting in permanent cell damage. To combat this oxidative stress, our research program is working to find effective strategies to deliver therapeutic doses of exogenous catalase to the cochlea. In the present study, we aimed (1) to evaluate whether our recombinant derivative of catalase, CAT‐SKL (which is designed to target the peroxisomes of cells) could protect against cisplatin‐induced cell death in vitro , and (2) to package CAT‐SKL into exosomes, and determine the safety, distribution and efficacy of this targeted antioxidant in vivo . In our first experiments, we assessed the safety and protective effects of CAT‐SKL using cochlear‐derived cells (HEI‐OC1) and WST‐1 cell viability assays. As predicted based on our previous studies in other tissues (e.g., brain, retina), CAT‐SKL was not harmful to HEI‐OC1 cells, and actually improved cell viability at higher concentrations. Importantly, CAT‐SKL offered significant protection against cisplatin‐induced ototoxicity, even when the doses of cisplatin exceeded levels known to cause damage. Motivated by this in vitro otoprotection, we then endeavored to package CAT‐SKL into exosomes, as this would provide a strategy to deliver the novel pharmaceutical in vivo . We packaged CAT‐SKL into macrophage‐derived exosomes (exoCAT‐SKL) via sonication, and purified the loaded exosomes using size exclusion chromatography. Successful loading of exoCAT‐SKL was confirmed using Western blotting and H202 decomposition assays. Next, adult mice were delivered intranasal administrations of a biotinylated version of CAT‐SKL packaged in exosomes, and their brains were then harvested and processed for streptavidin immunohistological staining. We observed extensive labelling of exoCAT‐SKL in the brains of these mice; evidence that intranasal administration not only effectively introduced our therapeutic into systemic circulation, but it was able to surpass tissue specific barriers that usually hinder uptake of therapeutics. Our ongoing experiments are investigating the bioavailability of repetitive intranasal dosing of exoCAT‐SKL in adult mice by harvesting their organs, and performing histopathological assessments. Once we have established the bioavailability of exoCAT‐SKL in the cochlea following intranasal delivery, we will be poised to investigate its efficacy at attenuating cisplatin‐induced ototoxicity in vivo . Based on our findings, we suggest that CAT‐SKL is a promising therapeutic for protection of cochlear cells from cisplatin‐induced ototoxicity, and that packaging CAT‐SKL into exosomes may offer an effective way to deliver therapeutic doses of this targeted antioxidant to cells undergoing oxidative stress. Support or Funding Information BrainsCAN, CIHR, The W. Garfield Weston Foundation This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .